Literature DB >> 9341896

Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma.

S Koyama1.   

Abstract

In this study, we evaluated the ability of combination regimens of interleukin-12 (IL-12) and interleukin-2 (IL-2) to induce effective killer cells against human tumors in vitro, in peripheral blood lymphocytes (PBL) from 15 cancer patients and mixed lymphocyte/tumor culture (MLTC) cells from 16 cancer patients, and carried out a phenotypic analysis of the cells responsible for the lysis of the human tumors. The freshly prepared PBL were cultivated with IL-2 alone or IL-12/IL-2 for 10 days [lymphokine-activated killer (LAK) cell generation system]. The MLTC cells (PBL cultured with mitomycin-C-treated allogeneic G-415 tumor cells for 3 days) were further cultivated with IL-2 or IL-12/IL-2 for 7 days [cytotoxic T lymphocytes (CTL) generation system]. The cytolytic activities of the lymphoid cells cultivated with IL-12/IL-2 were significantly augmented in both the LAK and CTL generation systems, as compared with those of cells treated with IL-2 alone. In the LAK generation system, the cytolytic activities of the cells cultivated with IL-12/IL-2 were significantly decreased by the method of negative selection of CD11b- or CD56+ cells using immunomagnetic beads. The CD8(+)-depleted cells showed a slight decrease of activity. The killer cell activities of the CD4(+)-depleted cells remained unchanged. In the CTL generation system, the activity was markedly reduced by the elimination of the CD8+ or CD11b+ or CD56+ cells. The combined data suggested that IL-12/IL-2-induced killer effector cells in the LAK generation system were mainly of the natural killer (NK) type, comprising CD8-CD11b+, CD8- CD16b+, CD3-CD56+, and partly possible CD8+ CD11b- T cells. CD8+ CD11b- T cells mixed with cells of the NK type, comprising CD8-CD11b+, CD8- CD16b+ and CD3-CD56+ cells, were the population of killer effector cells induced by IL-12/IL-2 in the CTL generation system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9341896     DOI: 10.1007/bf01192201

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  23 in total

1.  Regulation of human cytolytic lymphocyte responses by interleukin-12.

Authors:  M K Gately; A G Wolitzky; P M Quinn; R Chizzonite
Journal:  Cell Immunol       Date:  1992-08       Impact factor: 4.868

2.  Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells.

Authors:  M Aste-Amezaga; A D'Andrea; M Kubin; G Trinchieri
Journal:  Cell Immunol       Date:  1994-07       Impact factor: 4.868

Review 3.  Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes.

Authors:  G Trinchieri
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

4.  Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor).

Authors:  M K Gately; B B Desai; A G Wolitzky; P M Quinn; C M Dwyer; F J Podlaski; P C Familletti; F Sinigaglia; R Chizonnite; U Gubler
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

5.  Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells.

Authors:  J P Zou; N Yamamoto; T Fujii; H Takenaka; M Kobayashi; S H Herrmann; S F Wolf; H Fujiwara; T Hamaoka
Journal:  Int Immunol       Date:  1995-07       Impact factor: 4.823

6.  Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer.

Authors:  H J Zeh; S Hurd; W J Storkus; M T Lotze
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-08

7.  Phenotypic analysis of nylon-wool-adherent suppressor cells that inhibit the effector process of tumour cell lysis by lymphokine-activated killer cells in patients with advanced gastric carcinoma.

Authors:  S Koyama; K Fukao
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.

Authors:  M Kobayashi; L Fitz; M Ryan; R M Hewick; S C Clark; S Chan; R Loudon; F Sherman; B Perussia; G Trinchieri
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

9.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors.

Authors:  M J Brunda; L Luistro; R R Warrier; R B Wright; B R Hubbard; M Murphy; S F Wolf; M K Gately
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

10.  Differential activation of lymphokine-activated killer cells with different surface phenotypes by cultivation with recombinant interleukin 2 or T-cell growth factor in gastric cancer patients.

Authors:  S Koyama; T Ebihara; K Fukao; T Osuga
Journal:  Jpn J Cancer Res       Date:  1989-02
View more
  3 in total

1.  Apoptotic depletion of infiltrating mucosal lymphocytes associated with Fas ligand expression by Helicobacter pylori-infected gastric mucosal epithelium: human glandular stomach as a site of immune privilege.

Authors:  S Koyama
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

Review 2.  Immunotherapy of cancer by IL-12-based cytokine combinations.

Authors:  Jonathan M Weiss; Jeff J Subleski; Jon M Wigginton; Robert H Wiltrout
Journal:  Expert Opin Biol Ther       Date:  2007-11       Impact factor: 4.388

3.  Differential expression of proteins in naïve and IL-2 stimulated primary human NK cells identified by global proteomic analysis.

Authors:  Weifeng Cao; Arvinder Kapur; Di Ma; Mildred Felder; Cameron O Scarlett; Manish S Patankar; Lingjun Li
Journal:  J Proteomics       Date:  2013-06-25       Impact factor: 4.044

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.